CARDINAL HEALTH INC

Cardinal Health reported a strong fiscal year 2026 with revenue increasing 14% to $254.2 billion and non-GAAP diluted EPS rising 37% to $11.26. The company's Board of Directors approved a new $5.0 billion share repurchase program. Key drivers included the acquisition of Solaris Health for $1.9 billion and robust performance in its Pharmaceutical and Specialty Solutions segment, though results were partially offset by goodwill and equity impairments and ongoing tariff challenges.

Cardinal Health reported strong fourth quarter and fiscal year 2026 results, with Q4 revenue up 6% to $63.7 billion and non-GAAP diluted EPS increasing 40% to $2.91. For the full fiscal year 2026, revenues rose 14% to $254.2 billion, and non-GAAP diluted EPS grew 37% to $11.26. The company also provided positive fiscal year 2027 non-GAAP EPS guidance of $12.40 to $12.60, reflecting 13% to 15% growth, and announced a $5.0 billion increase to its share repurchase authorization.

Cardinal Health, Inc. has entered into a new $4.0 billion unsecured revolving credit agreement, effective August 7, 2026. This new facility, which matures on August 7, 2031, replaces the company's existing $2.0 billion five-year and $1.0 billion 364-day revolving credit facilities, as well as a $1.0 billion receivables sale facility. The company will utilize the new credit line for general corporate purposes and incurred no penalties for terminating the prior agreements.

Cardinal Health, Inc. announced the appointment of Anita Zielinski as its new Chief Accounting Officer, effective November 5, 2026. Ms. Zielinski will join the company as Senior Vice President Finance on September 16, 2026, and will succeed Mary Scherer. Ms. Zielinski brings extensive experience, having previously served as interim Chief Financial Officer and Senior Vice President, Chief Accounting Officer and Controller at Baxter International, Inc. Her compensation package includes an annual base salary, annual cash bonus, equity awards, a $750,000 cash sign-on bonus, and $1,000,000 in time-vesting restricted share units.

Cardinal Health reported strong third-quarter fiscal year 2026 results, with revenue increasing 11% to $60.9 billion and non-GAAP diluted EPS rising 35% to $3.17. Despite a GAAP operating earnings decrease due to a goodwill impairment, the company raised and narrowed its fiscal year 2026 non-GAAP EPS guidance to $10.70-$10.80. The company also reduced debt and completed an additional $250 million in share repurchases, bringing the fiscal year total to $1.0 billion. This performance was driven by strong operating results, particularly in Pharmaceutical and Specialty Solutions.